Drug Profile
Octreotide - Novartis
Alternative Names: Octreotide acetate; Octreotide hydrochloride; Octreotide LAI; Octreotide Long Acting Injectable; Octreotide pamoate; Oncolar; Sandostatin LAR Depot; SMS 201995 ac; SMS 201995 pa; SMS 201995 pa LAR; SMS pa; SMS-201-995; SMS-995; SMS-995-AAALatest Information Update: 05 Apr 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acromegaly; Intestinal obstruction; Malignant carcinoid syndrome; Neuroendocrine tumours
- Discontinued Diabetic retinopathy; Diarrhoea; Malignant thymoma; Polycystic liver disease; Prostate cancer
Most Recent Events
- 30 Mar 2023 Registered for Neuroendocrine tumours (Late stage disease) in European Union (IM) before March 2023
- 10 Aug 2020 CASI Pharmaceuticals plans a registrational trial for Neuroendocrine tumours or Acromegaly in China in 2020
- 16 Mar 2020 CASI Pharmaceuticals announces intention to obtain marketing approval for Acromegaly and Neuroendocrine tumours in China